As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Abvc Biopharma, Inc. The largest reported stake is Eugene Jiang's, at 18.5%. 2 filings are on record since July 15, 2025 (Schedule 13D/A, July 15, 2025).
Sell to companies like Abvc Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Abvc Biopharma, Inc. has 2 Schedule 13D or 13G filings on record since 2025-07-15. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 18.5% | 131,159 | SCHEDULE 13D/A, 2025-07-15 | 2025-07-10 | |
| Lind Global Fund II LP | 3.2% | 557,143 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
Holding shares or following this stake? See who's behind Abvc Biopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Abvc Biopharma, Inc. and the records around it.
Abvc Biopharma, Inc. elsewhere on the record
Companies that share a holder
- Lind Global Fund II LP also filed stake reports on 3 other companies: TENAX THERAPEUTICS, INC. (May 2026), WEBUY GLOBAL LTD (Aug 2025)
Watch Abvc Biopharma, Inc.
Get an email when Abvc Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Abvc Biopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Abvc Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abvc Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Eugene Jiang | 3,102,265 | 0 | 3,102,265 | 0 | SCHEDULE 13D/A, 2025-07-15 |
| Lind Global Fund II LP | 557,143 | 0 | 557,143 | 0 | SCHEDULE 13G/A, 2025-08-13 |
| Lind Global Partners II LLC | 557,143 | 0 | 557,143 | 0 | SCHEDULE 13G/A, 2025-08-13 |
| Easton Jeff | 557,143 | 0 | 557,143 | 0 | SCHEDULE 13G/A, 2025-08-13 |
The latest filing names Abvc Biopharma, Inc., with its principal executive office as 44370 OLD WARM SPRINGS BLVD., FREMONT, CA 94538 (SCHEDULE 13G/A, 2025-08-13).
Source of funds (Item 3)
The Reporting Person has acquired the subject securities in various ways since his original acquisition including but not limited to original issuances from the Issuer and equity compensation under the Issuers Equity Incentive Plan that the Reporting Person received as compensation for employment and Board membership. The Reporting Person also has voting rights to securities that the Reporting Person did not pay for. The Reporting Person holds 131,159 shares directly.Eugene Jiang, SCHEDULE 13D/A, 2025-07-15
Purpose of Transaction (Item 4)
Eugene Jiang
Certain of the Issuer's shareholders sought to grant the Reporting Person voting rights with respect to such shareholder's shares.Item 4 of the SCHEDULE 13D/A filed 2025-07-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Eugene Jiang | 18.5% | SCHEDULE 13D/A |
| 2025-08-13 | Lind Global Fund II LP | 3.2% | SCHEDULE 13G/A |
Questions about who owns Abvc Biopharma, Inc.
Who owns Abvc Biopharma, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Abvc Biopharma, Inc.: Eugene Jiang (18.5%, Schedule 13D/A, filed 2025-07-15).
When did Eugene Jiang buy into Abvc Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Eugene Jiang on this page is the Schedule 13D/A, filed 2025-07-15, reporting 18.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Abvc Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.